Overview
vst bio, a biotechnology company focused on vascular diseases, has closed a $45 million Series A financing round to advance its lead stroke therapy candidate, vb-001. The round was led by Coefficient Giving, a philanthropic funder dedicated to impactful scientific and global health initiatives, which has invested a total of $45 million in the company since its inception in 2020.
Products
Loading...
Recent Deals
Investors: Coefficient Giving
vst bio, a biotechnology company focused on vascular diseases, has closed a $45 million Series A financing round to advance its lead stroke therapy candidate, vb-001. The round was led by Coefficient Giving, a philanthropic funder dedicated to impactful scientific and global health initiatives, which has invested a total of $45 million in the company since its inception in 2020.